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Abstract
Background: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic
brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial
insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for
determining a patient’s risk for developing this pathology.
Methods: In the present study, we employed antibody array and Luminex-based screening methods to interrogate
the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS≤8) with or
without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm
the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and
polytrauma patients with TBI.
Results: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective
of their ICP status. However, the group of patients who subsequently experienced ICP ≥ 25 mm Hg had
significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained
≤20 mm Hg. When blinded samples (n = 22) were assessed, a serum IL-6 cut-off of <5 pg/ml correctly identified
100% of all the healthy volunteers, a cut-off of >128 pg/ml correctly identified 85% of isolated TBI patients who
subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all
patients whose ICP remained ≤20 mm Hg throughout the study period. In contrast, the marker had no prognostic
value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in
patients with orthopedic injury (n = 7) in the absence of TBI, a significant increase was found in these patients
compared to healthy volunteers, albeit lower than that observed in TBI patients.
Conclusions: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in
isolated TBI.
Background
Traumatic brain injury (TBI) is a leading cause of mor-
bidity and mortality among civilian and military popula-
tions. The initial injury sets in motion a number of
cellular and molecular events leading to the development
of secondary processes that profoundly influence out-
come. One of the major secondary pathologies is elevated
intracranial pressure (ICP). If not maintained below 20
mm Hg, elevated ICP can cause poor cerebral perfusion,
brain herniation, and death. In many cases, ICP rises in a
delayed manner, reaching its peak level between days 3-5
post-TBI [1]. Although no prophylactic treatment is cur-
rently available to prevent elevated ICP, neurointensivists
and neurosurgeons often use sedatives, mannitol, hyper-
tonic saline, cerebrospinal fluid drainage, decompressive
craniectomy, and/or barbiturate-induced coma to manage
this condition. Therefore, the identification of prognostic
biomarkers that can predict which patients are at risk of
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developing high ICP would help in managing severe TBI
patients.
Previous studies have implicated inflammatory pro-
cesses in ICP elevation [2,3]. Both pro- and anti-inflam-
matory cytokines have been reported to change as a
result of TBI and their combined action is thought to
determine the overall degree of inflammation [4]. Inter-
leukin-6 (IL-6) is a 20-30 kDa cytokine with pleiotropic
properties that has been shown to be a biomarker asso-
ciated with various disease states. For example, high
serum IL-6 correlates with coronary instability and caro-
tid plaques, has been shown to be a prognostic marker
for septic shock, and is an indicator of outcome in
severe intra-abdominal sepsis [5-7]. In TBI, a relation-
ship has been reported between the transcranial IL-6
gradient (venous-arterial) at the time of admission and
survivability [8]. In addition, a recent multiplex analysis
of putative serum biomarkers identified IL-6 as a marker
of inflicted pediatric TBI [9]. Although these studies
support the premise that inflammation-related proteins
such as IL-6 are elevated following TBI, it has not been
examined if the magnitude or duration of induction cor-
relates with the development of ICP.
In the present study, we utilized two screening meth-
ods, antibody arrays and multiplexing, to evaluate the
levels of interleukin family members in the serum of
healthy volunteers and in severe TBI patients (GCS≤8)
with and without incidence of ICP. Consistent with a
number of previous reports, we observed elevated IL-6
levels in TBI patients as compared to healthy volunteers.
Interestingly, the group of TBI patients who subse-
quently developed ICP ≥ 25 mm Hg had significantly
higher serum IL-6 levels within the first 17 hours of
injury as compared to the patients whose ICP remained
≤20 mm Hg during their hospital stay. However, in
polytrauma patients with TBI, serum IL-6 levels were
unable to differentiate between the two groups. IL-6
levels in patients with orthopedic injury were found to
be higher than those recorded in healthy volunteers, but
lower than seen in the TBI patients. Taken together, our
results suggest that for patients with isolated TBI, serum
IL-6 is a good prognostic biomarker for predicting sub-
sequent ICP elevations.
Methods
Recruitment and sample collection
All protocols regarding the use of human subjects were
reviewed and approved by the University of Texas Com-
mittee for the Protection of Human Subjects, and were
in compliance with the Helsinki Declaration. Blood sam-
ples were obtained specifically for the purpose of this
study and were coded to protect confidentiality. Non-
trauma volunteers were consented and enrolled by the
University of Texas Clinical Research Unit at Memorial
Hermann Hospital (Houston, TX). To be included in
the study, orthopedic injury patients admitted to the
Memorial Hermann Hospital Emergency Department
had to have a radiographically confirmed fracture, no
head trauma, no other known inflammatory process or
infection, no history of neurological or psychiatric disor-
ders, and no alcohol or drug dependency. Orthopedic
injury subjects were consented and a one-time blood
draw within 24 hr of the injury was taken. TBI patients
(14-65 years old) admitted to the adult neurotrauma
intensive care unit (NTICU) of Memorial Hermann
Hospital who had Glasgow Coma Scale (GCS) scores ≤8
and planned placement of an ICP monitor were
recruited, and consented (through their next-of-kin) for
participation in this study. ICP measurements were
measured continuously and recorded hourly from the
time of monitor placement. Elevated ICP was defined as
a ≥25 mm Hg measurement for at least 5 minutes that
occurred either twice in a 24 hr period, or on two con-
secutive days. No change in ICP was defined as an ICP
level of ≤20 mmHg throughout the 5 day study period.
Patients whose ICP fell between 20-25 mmHg on any of
the sampling days were not included in the present
study in order to provide a clear separation between the
two injury groups. An initial blood draw was obtained
at the earliest possible time after admission, patient sta-
bilization, and informed consent was obtained. To mini-
mize interference with clinical management, subsequent
blood samples were drawn after morning rounds were
completed (i.e. every 24 hours for first five days of hos-
pital admission). Relevant medical data was recorded
and coded to match the extracted blood sample. Serum
was isolated by centrifugation at 4°C using serum
separator tubes (Becton Dickinson, Franklin Lakes, NJ)
as described by the vendor. Aliquots were prepared and
frozen at -80°C until needed.
Patient management
All patients admitted to the NTICU of Memorial Her-
mann Hospital received standard care based on the
types and severities of their injuries. Patients were man-
aged to avoid hypoxia and hypotension, and to attempt
to maintain adequate cerebral blood flow (e.g., systolic
pressure above 90 mm Hg and a cerebral perfusion
pressure (CPP) of at least 60 mm Hg.). Head computed
tomography (CT) scans were performed on presentation
to the Emergency Department and repeated within
approximately 6 hours. Subsequent CTs were performed
based on the patient’s neurological status. Intracranial
pressure monitors were placed in those with a GCS ≤ 8,
or those with significant findings on head CT who in
the opinion of the attending neurosurgeon required
intracranial pressure monitoring. Any patient with an
operative lesion was transferred to the operating room
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emergently. The decision to remove a bone flap was
made by the attending neurosurgeon at his discretion.
Medications to prevent seizures were given prophylacti-
cally for the first 7 days of hospitalization. The patient’s
temperature was controlled to prevent the patient from
becoming hyperthermic. Patient’s intake and output
were monitored to assure that the patient received ade-
quate fluid volume. Sedation and analgesics were used
in all severe TBI patients. Drainage of CSF, mannitol
and/or hypertonic saline was used, as required, to lower
intracranial pressure. Refractory elevated ICP typically
went through the treatment continuum of sedation,
mannitol, CSF drainage, paralytics, barbiturate coma,
and decompressive craniectomy. With the exception of
those treatments initiated to control intracranial pres-
sure (e.g. mannitol, cranieotomy, etc.), the care did not
differ between the two study groups.
Patient assessments and classifications
Acute Physiology and Chronic Health Evaluation II
(APACHE II), GCS and Injury Severity Score (ISS).
APACHE II is designed to measure the severity of dis-
ease for newly admitted ICU patients [10]. The worst
value for each component of the scale in the first 24
hours of ICU admission was collected. GCS is a neuro-
logical assessment routinely used in clinical care and
neurosurgical research [11]. All injuries were classified
according to body region and given an abbreviated
injury score (AIS, The Abbreviated Injury Scale, 1990
Revision, Update 98) from 1 to 6 according to standar-
dized definitions (a score of 6 indicates death). The
worst three AIS scores in different body regions were
squared and summed to calculate the ISS. The ISS cor-
relates linearly with mortality, morbidity, length of hos-
pital stay, and other measures of injury severity [12].
Polytrauma was defined as a head injury along with an
AIS score ≥3 in a body region other than the head, neck
or face.
Human cytokine array
The levels of inflammation-related factors were assessed
using the Cytokine Array 2000 series (Ray Biotech, Nor-
cross, GA) as described by the vendor. Serum samples
(n = 14/group) collected within the first 24 hr of injury
were chosen from TBI patients whose ICP remained
≤20 mm Hg throughout the study period, and from TBI
patients whose maximum recorded ICP ≥ 25 mm Hg.
Samples were divided (n = 7/time point) based on their
collecting time into either 10 hr (± 4 hr) or 20 hr (± 4
hr) groups, then pooled. Pooled samples from age-,
race- and gender-matched healthy volunteers served as
baseline controls. The membranes were blocked against
non-specific binding for 2 hr using the 1× blocking buf-
fer provided in the assay kit. Pooled serum samples
were diluted 10-fold in 1× blocking buffer and incubated
on individual membranes overnight at 4°C with gentle
shaking. Following washing, biotinylated antibodies were
added for 2 hr. The binding of the biotinylated antibo-
dies was detected using a horseradish peroxidase-strep-
tavidin complex and a chemilumenescent substrate.
Signals were captured on BioMax light film (Perkin-
Elmer, Waltham, Massachusetts) and analyzed using
Image J densitometric software. All groups were assessed
simultaneously so that they were represented on the
same film. Multiple exposures were generated to ensure
the linearity of the signals. The cumulative optical densi-
ties of the resultant spots on each membrane were
summed and compared across membranes for normali-
zation purposes. Antibodies against each analyte were
represented in duplicate spots on each membrane, the
optical densities of which were averaged. Each pooled
sample was tested on two independent arrays.
Luminex
The levels of IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-17, and IL-1ra were determined using Luminex and
kits obtained from R&D Systems (Minneapolis, MN)
and the procedures were conducted as recommended by
the vendor. Briefly, a standard curve for each of the tar-
get proteins was prepared by serial dilution in assay buf-
fer. Serum samples were diluted 1:4. Standards and
samples were incubated in a 96-well filter-bottom plate
with target-specific microparticles for 2 hr at room tem-
perature with shaking. Following the incubation, micro-
particles were washed 3 times using the wash buffer
provided in the kit and a vacuum manifold. Biotinylated
antibodies were added and incubated for 1 hr, and
detected using a streptavidin-phycoerythrin conjugate.
Following extensive washing, samples were analyzed on
a Luminex plate reader. All samples were analyzed in
duplicate and the concentrations calculated by compari-
son to the appropriate standard curve.
Enzyme-linked immunosorbent assays (ELISAs)
To test the predictive power of changes in serum IL-6
proteins, sandwich ELISAs were performed using sam-
ples collected during the first 24 hr of injury. Samples
from healthy volunteers were used as controls. Samples
were coded so that the experimenter was unaware of
the group designation during the procedure. A standard
curve was prepared by serial dilution of purified recom-
binant protein supplied with the assay (R&D systems,
Minneapolis, MN). Standards and serum samples (in tri-
plicate) were added to a 96-well plate containing immo-
bilized antibodies specific to IL-6. Samples were
incubated at room temperature for 2 hours, with gentle
shaking. Following extensive washing, bound IL-6 was
detected using an HRP-conjugated polyclonal antibody
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against the target protein. The detection antibody was
incubated for 2 hr at room temperature, and detected
using 2,2’-Azino-bis-(3-ethylbenzthiazoline-6-sulfonic
acid) and 3% H2O2. The reaction was terminated by the
addition of sulfuric acid provided in the kit. The resul-
tant optical density was detected using a microplate
reader at 450 nm with a wavelength correction reading
at 540 nm. The concentrations of the unknowns were
calculated from the standard curve using SigmaPlot
(Systat Software, Inc, San Jose CA).
Statistical analysis
A power analysis based on approximated magnitudes of
change and technique reproducibility was performed a
priori to estimate the group sizes expected to provide
statistically significant results. All data was assessed
using a Kolmogorov-Smirnov test to determine normal
distribution. Time course data was compared using a
two-way ANOVA. Data for two-group or multiple
group comparisons at a single time point were analyzed
using a Students t-test or one-way ANOVA, respectively.
Any data that did not have a normal distribution was
assessed using non-parametric measures (e.g. ANOVA
on Ranks). Data are presented as the mean ± SEM
unless otherwise indicated, and the median value and
data range are provided where appropriate.
Results
Interleukin family member expression in the serum of TBI
patients with/without elevated ICP
To determine if the serum levels of interleukin family
members can be used to differentiate TBI patients based
on whether or not they will have a subsequent elevation
in ICP, two screening approaches were utilized: 1) anti-
body arrays using pooled serum samples from healthy
volunteers and TBI patients with/without incidence of
ICP ≥ 25 mm Hg, and 2) Luminex analysis of individual
serum samples from independent patients belonging to
the same groups.
Experiment 1: Antibody array
Using the recorded ICP values for the TBI patients
enrolled in this study, patients were divided into either
elevated ICP (ICP ≥ 25 mm Hg) or no-ICP groups (ICP
≤ 20 mm Hg). Age-, race- and gender-matched healthy
volunteers were selected and used as controls. The
demographics of the patients used in this study are
listed in Table 1. Figure 1A shows that when the maxi-
mum recorded ICP levels each day were plotted as a
function of time, the elevated ICP group had a delayed
increase in ICP, reaching a maximum between days 3
and 5 post-injury. By comparison, the patients without
incidence of elevated ICP had pressure values that
remained below the treatment level of 20 mm Hg
throughout the study period. Although it appears that
the initial ICP values in the ICP ≥ 25 mm Hg group are
higher than those detected in the ICP ≤ 20 mm Hg
group, correlation analysis revealed that initial ICP is
not a strong predictor of subsequent ICP elevations.
When the ICP values were analyzed to determine if
there was a correlation between initial ICP value (day 1)
and those recorded on days 3-5 (the time points at
which ICP ≥ 25 mm Hg were observed), correlation
coefficients of 0.596 (day 3), 0.241 (day 4), and 0.173
(day 5) were calculated.
As the principle aim of the current study was to deter-
mine if the initial levels of interleukin family members
could be used to identify patients at risk for developing
elevated ICP, serum samples from each of the groups
were further subdivided based on their collection time.
Pools of samples were prepared corresponding to either
10 ± 4 hr or 20 ± 4 hr post-injury (n = 7/group), and
applied to a cytokine array as directed by the vendor
(Ray Biosciences). Figure 1B shows representative
images of the resultant blots indicating the relative
Table 1 Demographic and clinical information for subjects used for pooled samples for RayBioscience assays.
Healthy Volunteers (n = 14) ICP ≤20 mm Hg (n = 14) ICP ≥25 mm Hg (n = 14)
Age range 22-39 years 15-48 years 14-56 years
Age (average) 26.2 ± 4.7 years 24.4 ± 9.2 years 28.1 ± 14.8 years
Race 10 Caucasians 11 Caucasians 12 Caucasians
3 African-Americans 3 African-Americans 1 African-American
1 Asian 1 Asian
Ethnicity 11 non-hispanics 9 non-hispanics 6 non-hispanics
3 non-hispanics 5 hispanics 8 hispanics
Gender 11 male 12 male 12 male
3 female 2 female 2 female
Apache II score N/A 18.8 ± 6.0 20.2 ± 4.1
ISS N/A 27.9 ± 6.4 23.0 ± 8.4
Data is presented as mean ± SEM.
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immunoreactivities for IL-10, IL-13, IL-15, IL-16, IL-1a,
IL-1b, Il-1ra, IL-2, IL-3, IL-4, Il-5, IL-6 and IL-7. Quan-
tification of the optical densities for these cytokines
revealed that while the serum levels of IL-6 were drama-
tically elevated in both TBI groups relative to that
observed in the healthy volunteers, the magnitude of
increase seen in the TBI patients with ICP ≥ 25 mm Hg
was significantly higher than that seen in the TBI
patients whose ICP remained ≤20 mm Hg throughout
the study period (relative immunoreactivity: healthy
volunteers = 100.0 ± 16.96%, ICP ≤ 20 mm Hg = 217.5
± 26.95%, ICP ≥ 25 mm Hg = 842.7 ± 112.96%; signifi-
cant interaction by two-way ANOVA F(1,8) = 12.835,
P = 0.007) (Figure 1C). No significant change was
detected in any of the other cytokines interrogated.
Experiment 2: Luminex
Since the above analysis was performed using pooled
samples, it raised the possibility that a large increase in
IL-6 levels within a few of the patients would have been
sufficient to increase the level of this protein in the entire
pooled sample. To address this concern, Luminex analy-
sis was performed using individual serum samples from
independent study subjects. The demographics of the
subjects used in this study are presented in Table 2. Fig-
ure 2A shows that these patients, similar to those chosen
for the antibody array screen, had ICP levels that either
remained ≤20 mm Hg throughout the study period, or
had a delayed increase in ICP that necessitated interven-
tion. As in Experiment 1, the ICP values recorded for
these patients on day1 was found to not be a strong pre-
dictor of the maximum ICP values recorded on day3
(correlation coefficient = 0.626), day4 (correlation coeffi-
cient = 0.353), or day5 (correlation coefficient = 0.152).
Luminex analysis was performed using analyte kits
available for multiplexing from R&D Systems (Minnea-
polis, MN). The interleukin family members interro-
gated were IL-10, IL-17, IL-1a, IL-1b, IL-1ra, IL-2, IL-4,
IL-5, and IL-6. Standard curves for each of the analytes
were generated using purified proteins supplied by the
vendor, and used to calculate the concentration of the
target protein in each of the individual samples. A
representative standard curve generated for IL-6 is
shown in Figure 2B. Similar to that observed using the
antibody array, when the levels of serum IL-6 were com-
pared between the healthy volunteers and TBI patients,
a dramatic increase in the level of this protein was
observed as a result of injury (Figure 2C). Of importance
is the observation that the initial levels of IL-6 recorded
in TBI patients that would subsequently develop ele-
vated ICP were significantly higher than that observed
in TBI patients whose ICP remained below 20 mm Hg
(group main effect by two-way ANOVA F(1,3) = 6.541,
P = 0.016). When organized according to time from ICP
(the day ICP was first recorded to exceed 25 mm Hg was
Figure 1 Identification of serum IL-6 as a marker of elevated
ICP by antibody arrays. A. Time course of ICP in patients classified
as having elevated ICP (ICP ≥ 25 mm Hg) versus that recorded in
patients whose ICP remained below 20 mm Hg for the duration of
the sampling period. B. Representative picture of a Ray Biosciences
Cytokine array showing the immunoreactivity of interleukin family
members in pooled samples (n = 7/pool) from healthy volunteers,
TBI patients with elevated ICP, and TBI patients whose ICP remained
below 20 mm Hg for the duration of the 5 day sampling period. C.
Summary data (presented as % healthy volunteer(HV)) showing that
the relative signal of IL-6 is significantly increased in patients with
ICP ≥ 25 mm Hg compared to patients whose ICP remained below
20 mm Hg throughout the study period. Data is presented as mean
± SEM. ‡, significant difference by two-way ANOVA.
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designated as day 0), the significant increase in IL-6 levels
was observed to occur, on average, two days prior to the
recorded time of ICP elevation (group main effect by two-
way ANOVA F(1,3) = 4.040, P = 0.049) (Figure 2D). All
other cytokines, with the exception of IL-1ra, were below
the detection limit of the Luminex assay. Serum IL-1ra
(data not shown), although elevated as a result of TBI, was
not significantly different between the ICP groups.
Prognostic accuracy of IL-6 for predicting ICP in TBI
patients
Based on the results of the Luminex screening, cut-off
values of ≥128 pg/ml (ICP ≥ 25 mm Hg), 5.1-127.9 pg/ml
(for ICP ≤ 20 mm Hg), and ≤5 pg/ml (for healthy
volunteers) serum IL-6 were identified as being able to
stratify the patient groups. To test the accuracy of these
cut-off values, ELISAs were performed using samples
that were blinded as to their group designations. Prior to
initiating these studies, randomly chosen serum samples
used for Luminex analysis were re-probed using an IL-6
ELISA to determine the consistency of the measure-
ments. Table 3 shows the recorded values for each of the
samples. The table shows that 7 out of 8 (87.5%) samples
identified as having serum IL-6 values ≥128 pg/ml by
Luminex also giving values ≥128 pg/ml by ELISA. Simi-
larly, 75% of samples with serum IL-6 concentrations
between 5.1-127.9 pg/ml were found to be in this range
by ELISA.
Table 2 Demographic and clinical information for subjects used for Luminex analysis. Data is presented as mean ±
SEM.
Healthy Volunteers (n = 10) ICP ≤20 mm Hg
(n = 9)
ICP ≥25 mm Hg (n = 10)
Age range 20-39 years 19-51 years 14-54 years
Age (average) 26.5 ± 5.5 years 29.5 ± 12.1 years 29.3 ± 11.2 years
Gender 8 male 6 male 9 male
2 female 3 female 1 female
Race 8 Caucasians 8 Caucasians 9 Caucasians
1 African-Americans 1 African-Americans 1 African-American
1 Asian
Ethnicity 5 non-hispanics 6 non-hispanics 6 non-hispanics
5 non-hispanics 3 hispanics 4 hispanics
Apache II score N/A 17.6 ± 3.7 21.2 ± 3.5
ISS N/A 23.6 ± 5.4 19.8 ± 3.6
Therapy intensity level
first 24 hr N/A 4.0 ± 1.8 5.1 ± 4.1
72-120 hr N/A 3.2 ± 1.8 5.2 ± 4.0
Mortality at time of discharge N/A 0/9 (0%) 2/10 (20%)
Mechanism of injury N/A
motorcycle collision 3/9 (33%) 3/10 (30%)
motor vehicle accident 5/9 (55%)a 5/10 (50%)
fall 0/9 (0%) 2/10 (20%)b
assault 1/9 (11%) 0/10 (0%)
Initial CT resultsc N/A
skull fracture 5/9 (56%) 5/10 (50%)
subarachnoid hemorrhage 6/9 (67%) 7/10 (70%)
epidural hematoma 3/9 (33%) 1/10 (10%)
subdural hematoma 3/9 (33%) 8/10 (80%)
intraventricular hemorrhage 4/9 (44%) 3/10 (33%)
contusion 7/9 (78%) 8/10 (80%)
midline shift 3/9 (33%) 3/10 (30%)
edema 5/9 (56%) 3/10 (30%)
diffuse axonal injury 0/9 (0%) 1/10 (10%)
a, one subject was assaulted after motor vehicle accident
b, one subject fell off a moving vehicle
c, some patients may present with more than one pathology.
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De-identified samples from healthy volunteers and
TBI patients, whose first sample draw occurred during
the first 17 hr of injury, were analyzed for IL-6 levels
using ELISA. This time point was chosen as it repre-
sented the latest time at which IL-6 serum concentra-
tions were found to be consistently elevated in the ICP
≥ 25 mm Hg group by the antibody array and Luminex
analyses. Predetermined cut-off values, based on the
Luminex analysis, of ≤5 pg/ml for healthy volunteers,
5-127.9 pg/ml for ICP ≤ 20 mm Hg and ≥128 pg/ml
for ICP ≥ 25 mm Hg, were used to classify the de-
identified samples. Table 4 shows the measured con-
centrations of IL-6 in these samples, along with the
predicted and actual group designations. The results
show that serum IL-6 concentrations could be used to
correctly classify 7 of 7 healthy volunteers, and 15 of
15 injured patients. Of the injured patients, 6 of 8
were correctly identified as belonging to the ICP ≤ 20
mm Hg group, and 6 of 7 correctly identified as having
a subsequent ICP elevation (85.7% sensitivity, 75% spe-
cificity) at the cut-off values employed. Compilation of
all the recorded IL-6 values for the ICP ≤ 20 mm Hg
and ICP ≥ 25 mm Hg groups yielded a receiver opera-
tor characteristic curve with an area under the curve
of 0.81, suggesting that IL-6 is a good prognostic mar-
ker for ICP in isolated brain injury.
Figure 2 Early increase in serum IL-6 can be used to stratify TBI patients based on risk for developing elevated ICP. A. Time course of
ICP in patients classified as having elevated ICP (ICP > 25 mm Hg) versus that recorded in patients whose ICP remained below 20 mm Hg for
the duration of the sampling period. B. Standard curve showing the relationship between increasing IL-6 concentrations and the mean
fluorescent intensity (MFI) detected by Luminex analysis. C. Summary data showing the levels of IL-6 detected in the serum of healthy volunteers
(HV), from TBI patients with elevated ICP (ICP > 25 mm Hg), and from patients whose ICP remained below 20 mm Hg throughout the study
period. D. Luminex data organized based on time of sample withdrawal relative to the subsequent increase in ICP. Day 0 represents the time
point at which the ICP was recorded to surpass 25 mm Hg. Each patient with an elevation in ICP was paired with a patient whose ICP remained
≤20 mm Hg throughout the study period. Data is presented as mean ± SEM. ‡, significant difference by two-way ANOVA.
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We next questioned if the increase in IL-6 levels
observed in patients whose ICP subsequently elevated
to ≥25 mm Hg could be correlated to the degree (mag-
nitude, frequency or duration) of ICP elevation. ICP
profiles from individual patients were generated using
data recorded hourly by the nursing staff. Figure 3A
shows representative ICP profiles from TBI patients
whose ICP remained below the threshold for therapeu-
tic intervention (20 mm Hg; dotted line). Patients with
elevated ICP, by comparison, had several ICP spikes
that necessitated ICP management (Figure 3B). To
determine if the degree of ICP elevation correlated
with initial IL-6 values, the number of spikes over 20
mm Hg, the maximum recorded ICP value, and the
area under the curve (AUC) for the ICP values over 20
mm Hg were calculated for the 5 day monitoring per-
iod. Correlation analysis revealed that there was no
correlation between the level of IL-6 and either the
Table 3 Comparison of IL-6 concentrations detected in 20 randomly chosen serum samples detected using Luminex
and conventional ELISA analyses.
Sample Luminex ELISA Sample Luminex ELISA
1 69.8 pg/ml 76.3 pg/ml 11 130.8 pg/ml 153.1 pg/ml
2 62.5 pg/ml 69.4 pg/ml 12 902.1 pg/ml 54.7 pg/ml
3 883.5 pg/ml >600 pg/ml 13 268.2 pg/ml 322.2 pg/ml
4 116.2 pg/ml 148.6 pg/ml 14 47.4 pg/ml 57.5 pg/ml
5 110.1 pg/ml 179.7 pg/ml 15 28.9 pg/ml 61.7 pg/ml
6 154.6 pg/ml 172.5 pg/ml 16 204.4 pg/ml 257.0 pg/ml
7 43.6 pg/ml 63.5 pg/ml 17 57.2 pg/ml 93.4 pg/ml
8 83.5 pg/ml 124.2 pg/ml 18 59.7 pg/ml 89.7 pg/ml
9 883.5 pg/ml >600 pg/ml 19 160.1 pg/ml 204.5 pg/ml
10 28.1 pg/ml 43.5 pg/ml 20 30.7 pg/ml 36.9 pg/ml
Table 4 Diagnostic accuracy of IL-6 for predicting subsequent elevations in ICP.
Maximum ICP (mm Hg) ELISA (pg/ml IL-6) Classification Actual
1 NA undetectable HV HV
2 NA undetectable HV HV
3 NA undetectable HV HV
4 NA 2.01 HV HV
5 NA undetectable HV HV
6 NA undetectable HV HV
7 NA undetectable HV HV
8 20 76.31 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
9 16 148.58 ICP ≥ 25 mm Hg ICP ≤ 20 mm Hg
10 20 54.66 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
11 19 63.53 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
12 20 251.51 ICP ≥ 25 mm Hg ICP ≤ 20 mm Hg
13 16 57.48 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
14 19 93.45 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
15 20 94.6 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
16 30 188.17 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
17 28 573.01 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
18 26 152.78 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
19 31 >600 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
20 31 172.46 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
21 38 >600 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
22 30 43.52 ICP ≤ 20 mm Hg ICP ≥ 25 mm Hg
Blinded samples, taken within the first 16 hr of injury (or from paired healthy volunteers), were analyzed for IL-6 content. HV: healthy volunteer
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number of ICP events (correlation coefficient = -0.23),
the maximum ICP value (correlation coefficient
= 0.20), or the AUC (correlation coefficient = -0.24).
However, since all the patients in this study received
treatment if their ICP passed 20 mmHg, the ICP pro-
files recorded (magnitude, frequency and duration) are
likely to have been influenced by the treatments being
instituted for each patient.
Prognostic accuracy of IL-6 for predicting ICP in
polytrauma patients
As TBI often occurs in the presence of bodily trauma,
and serum IL-6 levels have been shown to increase fol-
lowing other injuries, we questioned if the prognostic
accuracy of this biomarker in identifying TBI patients at
risk for developing elevated ICP would be compromised
by polytrauma. Polytrauma was defined as a head injury
along with an injury to another body region that
received an AIS score ≥3. De-identified samples from
these patients were analyzed for serum IL-6 content and
group designations assigned using the aforementioned
cut-off values. The results presented in the Table 5
show that serum IL-6 concentrations could be used to
only correctly classify 6 of the 11 polytrauma patients
tested (54.5%) based on their ICP status.
Increases in IL-6 levels in patients with orthopedic injury
The loss of prognostic accuracy of serum IL-6 in poly-
trauma patients suggests that the presence of other bod-
ily injuries may be altering serum IL-6 levels. To
address this possibility, we measured its concentration
in patients with orthopedic injury (n = 7) in the absence
of a TBI diagnosis (GCS = 15). Serum samples from
these patients were collected within 24 hrs of injury.
Table 6 shows the type of injury and serum IL-6 con-
centrations recorded in these individuals. On average,
serum IL-6 was found to be significantly elevated as a
result of orthopedic injury as compared to healthy
volunteers (healthy volunteers = 0.98 ± 0.37 pg/ml vs
Figure 3 Representative ICP profiles for TBI patients. ICP profiles for TBI patients whose ICP A. remained ≤20 mm Hg throughout the 5 day
study period and B. elevated to ≥25 mm Hg. Dotted line represents 20 mm Hg, the threshold for clinical intervention.
Table 5 Diagnostic accuracy of IL-6 for predicting
subsequent elevations in ICP in patients with
polytrauma.
Maximum
ICP (mm Hg)
IL-6 (pg/ml) Classification Actual
1 NA undetectable HV HV
2 NA 2.06 HV HV
3 NA 1.44 HV HV
4 11 >600 ICP ≥ 25 mm Hg ICP ≤ 20 mm Hg
5 16 140.28 ICP ≥ 25 mm Hg ICP ≤ 20 mm Hg
6 20 50.01 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
7 20 518.70 ICP ≥ 25 mm Hg ICP ≤ 20 mm Hg
8 12 75.00 ICP ≤ 20 mm Hg ICP ≤ 20 mm Hg
9 34 85.21 ICP ≤ 20 mm Hg ICP ≥ 25 mm Hg
10 32 342.89 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
11 28 189.76 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
12 38 30.91 ICP ≤ 20 mm Hg ICP ≥ 25 mm Hg
13 34 236.90 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
14 26 466.18 ICP ≥ 25 mm Hg ICP ≥ 25 mm Hg
Blinded samples taken within the first 16 hr of injury (or from paired healthy
volunteers) were analyzed for IL-6 content. Serum IL-6 concentrations could
be used to correctly identify only 6 of the 11 polytrauma patients tested
(54%). HV: healthy volunteer.
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orthopedic injury = 35.09 ± 14.02 pg/ml, p = 0.002)
(Figure 4A). Although elevated, these levels were found
to be significantly lower than those detected in isolated
TBI (one-way ANOVA on Ranks: H = 12.076, P =
0.002; Figure 4B) and in polytrauma patients (one-way
ANOVA on Ranks: H = 8.157, P = 0.017; Figure 4C).
Interestingly, while the orthopedic injury patients were
found have a serum IL-6 levels that were significantly
lower than both polytrauma groups (i.e. ICP ≤ 20 mm
Hg and ICP ≥ 25 mm Hg), they were not different than
that observed in the isolated TBI patients whose ICP
remained lower than 20 mm Hg (Figure 4B and 4C).
This suggests a general increase in serum IL-6 levels as
a result of polytrauma.
Discussion
In the present study, we employed two independent cyto-
kine screening platforms to identify serum IL-6 as a
prognostic biomarker for ICP elevation following TBI.
To the best of our knowledge, this is the first report to
indicate that serum IL-6 levels can be used as a prognos-
tic biomarker for elevated ICP in patients with isolated
TBI. Although we observed a change in serum IL-6 levels
in TBI patients, the present study does not indicate if the
increased IL-6 we measured originated in the injured
brain, or was the result of a peripheral response to the
injury. Previous studies have shown that injury to the
brain can cause both localized and systemic inflammatory
reactions [13-15]. In the brain, neurons, astrocytes and
microglia have all been shown to express IL-6 [16-19],
and it has been argued that this production is the main
source of IL-6 in the serum following TBI. For example,
arterial and jugular differences in IL-6 concentration
have been observed in TBI patients [8,20]. Furthermore,
IL-6 is the cytokine that is present in the highest concen-
tration in human CSF after TBI [21], reaching peak con-
centrations of up to 30,000 pg/ml [22]. By comparison,
peak serum concentrations of IL-6 have been reported to
only reach 1090 pg/ml during the same time period [23].
Taken together, these studies suggest that the increase in
serum IL-6 levels we observed may have originated in the
injured brain, rather than the result of a peripheral
response to the injury.
A number of studies have reported that increased IL-6
levels in the CSF correlate with favorable outcome after
Table 6 Serum IL-6 levels in orthopedic injury patients
without diagnosis of brain injury.
Patient Injury ELISA (pg/ml
IL-6)
1 Right metacarpel fracture 14.68
2 Open tibia/fibia fracture, fractures of lumbar
vertebrae and coccyx
100.89
3 Crush injury to right leg 24.63
4 Communited fracture of right femur midshaft 53.88
5 Bimalleolar fracture of ankle 1.71
6 Crushed foot, closed tibia and fibia fracture 31.93
7 Trimalleolar fracture of right ankle 7.21
Samples were taken within the first 24 hr of injury.
Figure 4 Orthopedic injury increases serum IL-6 levels. A.
Summary data showing the mean serum IL-6 concentrations for
healthy volunteers (HV) and orthopedic injury patients. Serum IL-6
levels were significantly lower in orthopedic injury patients
compared to TBI patients with B. isolated brain injury and C.
polytrauma. Data is presented as mean ± SEM. *, P < 0.05.
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brain injury [8,24-26]. For example, an in vivo microdia-
lysis study has shown that increased parenchymal IL-6
levels following TBI correlates with survival and
improved Galsgow Outcome Score (GOS) [26]. In addi-
tion, Chiaretti et al., [27] reported that early increases in
CSF IL-6 levels are associated with improved neurologic
outcome in children with severe TBI. In contrast to
these influences of IL-6 in the CSF, elevated serum IL-6
has been shown to correlate with multi-organ failure
and death following TBI [28,29], and is associated with
poor neurological outcome following hemorrhagic
stroke [30]. Serum levels of IL-6 ranging from 663.3 pg/
mL to 1060.9 pg/mL have been documented to occur
following brain death [31]. In non-CNS diseases, high
serum IL-6 levels have been correlated to poor survival
of breast cancer [32], are thought to be proatherogenic
[33], and are strong predictors of mortality in patients
with end-stage renal disease [34]. The reason for these
apparent differential effects of IL-6 is not known, but
may be dependent on the affected cell types. For exam-
ple, IL-6 has been reported to reduce glutamate- and
NMDA-induced neuronal death [35,36], and its loss is
associated with increased oxidative stress and neurode-
generation after injury [37]. In contrast, transgenic mice
overexpressing IL-6 in glial cells show ataxia, seizures
and extensive neurodegeneration [38]. Although the
relationship between high serum IL-6 and the develop-
ment of ICP is not clear at present, our findings are
consistent with previous observations that high serum
IL-6 levels are often associated with poor outcome.
Future basic and clinical studies using IL-6 receptor
blockers such as Tocilizumab (an anti-IL6R used to
treat rheumatoid arthritis) are needed to establish a role
for IL-6 in the progression of this secondary pathology.
In polytrauma patients, IL-6 can also be released into
the circulation as a result of injury to other organs.
Many cell types including monocytes, macrophages,
fibroblast, keratinocytes, smooth muscle cells, T cells,
and B cells have all been shown to increase IL-6 pro-
duction in response to injury [39-43]. This extracranial
production would be expected to further elevate serum
IL-6 and exacerbate outcome. Consistent with this,
Hensler et al., [44] reported that the serum concentra-
tions of a number of cytokines, including IL-6, in
patients with multiple injuries with TBI is higher than
that observed in isolated TBI. Although we did not
observe a significant group-wide increase in IL-6 levels
as a result of polytrauma, the presence of other injuries
appears to have reduced the prognostic accuracy of this
marker in identifying patients at risk for developing ele-
vated ICP. In support of this possibility, we observed
that patients with orthopedic injuries in the absence of
TBI had significantly higher serum IL-6 levels than
those observed in healthy volunteers. Extracranial
sources of IL-6 such as those observed in the orthopedic
injury patients may have contributed to the increase in
IL-6 levels seen in polytrauma patients whose ICP
remained below 20 mm Hg (Figure 3C), making them
indistinguishable from patients whose ICP ≥ 25 mm Hg.
However, due to the variety of extracranial injuries
observed in the polytrauma patients (e.g. ruptured
spleen, burns, fractures, etc.), it is not clear if different
cut-off values, time of sampling, or further sub-classifi-
cation based on type(s) of bodily injury, could be
employed to increase the sensitivity of this marker for
use in polytrauma.
Although IL-6 appears to lack sufficient specificity to
diagnose or detect brain injury, our study suggests that
it may have utility as a biomarker capable of predicting
patients with isolated TBI who are at risk for developing
elevated ICP, being able to identify these patients up to
2 days prior to the recorded increases in ICP. Previous
studies have indicated that the CNS specific proteins
glial fibrillary acidic protein (GFAP), cleaved tau (C-tau)
and neuron-specific enolase (NSE) also have some prog-
nostic capacity in identifying TBI patients at risk for
developing elevated ICP [45-47]. For example, Zemlan
et al., have reported that a high initial C-tau level in the
CSF of TBI patients is a good predictor of elevated ICP
[45]. However, recent studies have shown that the pro-
cess of CSF drainage can not only change ICP, but
depending on the method of drainage (continuous ver-
sus intermittent), can also dramatically influence CSF
biomarker levels [48]. In the serum, S100B and GFAP
concentrations have been shown to be lower in patients
with ICP < 25 mm Hg than in patients with ICP > 25
mm Hg [46]. While S100B has been demonstrated to
have extracranial sources, serum GFAP levels are not
increased by non-head injuries [46,49]. In addition to
these CNS proteins, we have recently demonstrated that
the levels of serum ceruloplasmin, the major copper car-
rier in the blood, transiently decrease in TBI patients
who will develop elevated ICP, and that this reduction
can be used as a sensitive prognostic marker of subse-
quent ICP increases [50]. It is therefore suggested that a
combination of biomarkers could be developed that cou-
ples IL-6, other identified biomarkers, and routine diag-
nostic evaluation of patient injuries, to create a
biomarker signature that predicts the occurrence of ele-
vated ICP with both high sensitivity and specificity.
Conclusions
Our results indicate that the initial level of serum IL-6
(within 17 hours of injury) can be used to identify iso-
lated TBI patients at risk for developing elevated intra-
cranial pressure. As this increase was observed, on
average, 2 days prior to the recorded increase in ICP,
this would allow sufficient time for physicians and
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caretakers to allocate resources and/or transport the
patient so that appropriate ICP management procedures
can be employed.
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